Coherus Oncology (CHRS) Operating Income Growth (1y) (2014 - 2026)

Coherus Oncology (CHRS) Operating Income Growth (1y) (2014 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Op. Inc Growth (1y) (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 2,150.96%
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 80.62%
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 8.65%
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn 183.45%
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 Coherus Oncology 194.37 Mn 27.32 Mn 8.50 Mn 20.43%

Historic Data

Download Data
DateValue
Mar 31, 2026 20.43%
Dec 31, 2025 -1.09%
Sep 30, 2025 5.38%
Jun 30, 2025 -14.79%
Mar 31, 2025 32.97%
Dec 31, 2024 34.14%
Sep 30, 2024 -46.40%
Jun 30, 2024 -14.71%
Mar 31, 2024 -0.06%
Dec 31, 2023 -33.81%
Sep 30, 2023 60.22%
Jun 30, 2023 21.52%
Mar 31, 2023 16.29%
Dec 31, 2022 -30.21%
Sep 30, 2022 -145.37%
Jun 30, 2022 -82.14%
Mar 31, 2022 51.65%
Dec 31, 2021 -340.77%
Sep 30, 2021 -197.24%
Jun 30, 2021 -137.00%